AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships

Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships. Dr. Rabinowitz brings over two decades of experience in clinical cardiology and healthcare strategy, currently serving as Clinical Associate Professor in Cardiology at UBC and previously as Director of the Coronary Care Unit at St. Paul's Hospital.

Dr. Rabinowitz's expertise spans entrepreneurial ventures in advanced diagnostics and personalized medicine, with a focus on integrating artificial intelligence in cardiology. He holds a medical degree from the University of Cape Town, with specializations from the University of Toronto and UBC.

The company also announced a stock option grant of 400,000 shares at $0.105 per share to an officer, vesting quarterly over two years. AIML focuses on AI and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal, and AI Rx.

Positive

• Appointment of experienced cardiology expert as CMO strengthens medical leadership
• Strategic addition to enhance AI-driven healthcare solutions development

Negative

• Dilutive effect of 400,000 new stock options grant at $0.105 per share

News Market Reaction – AIMLF

-2.78%

-2.78% Session move

In the trading session that priced this news, AIMLF declined 2.78%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Cardiologist and Visionary Joins Executive Leadership Team

• Reinforces Commitment to Cutting-Edge Digital Healthcare Solutions

VANCOUVER, BC / ACCESS Newswire / January 27, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Alan Rabinowitz, a globally recognized leader in cardiology and healthcare innovation, as Chief Medical Officer (CMO) and Director of Medical Partnerships. Dr. Rabinowitz's exceptional expertise will be instrumental in guiding AIML's next generation of AI-driven healthcare solutions.

Dr. Rabinowitz has a dynamic career spanning over two decades in clinical cardiology and healthcare strategy. He served as Director of the Coronary Care Unit at St. Paul's Hospital and is currently a Clinical Associate Professor in the Division of Cardiology at the University of British Columbia ("UBC"). A sought-after advisor to healthcare organizations worldwide, Dr. Rabinowitz is known for pioneering approaches to disruptive innovation, healthcare technology integration, and data-driven medicine.

In addition to his academic and clinical contributions, Dr. Rabinowitz has led numerous entrepreneurial ventures, with a particular focus on transforming patient care through advanced diagnostics and personalized medicine. He has been a key contributor to projects that integrate artificial intelligence with cardiology, enabling faster, more accurate diagnostics and proactive patient management. Dr. Rabinowitz holds a medical degree from the University of Cape Town, with further specialization in internal medicine and cardiology at the University of Toronto, followed by interventional cardiology training at UBC.

Paul Duffy, CEO of AIML, comments "Dr. Rabinowitz is a visionary leader in the field of cardiology and digital health innovation. His extensive clinical and entrepreneurial experience will be invaluable as we expand our portfolio of AI-driven healthcare solutions. His leadership strengthens our ability to deliver transformative technologies that empower patients and improve healthcare outcomes globally."

Mark Orsmond, Executive Chairman of AIML, added "The addition of Dr. Rabinowitz to our leadership team underscores AIML's unwavering commitment to advancing healthcare innovation. His contributions will play a pivotal role in shaping our strategic direction and accelerating our impact in the digital health sector."

Stock Option Grant

The Company further announces the grant of stock options to an officer of the Company to purchase up to 400,000 common shares of the Company ("Shares") at an exercise price of $0.105 per Share for a term of five years ("Options"). The Options vest ¼ every 6 months, with the first vest occurring on the date of grant.

For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

About AI/ML Innovations Inc. https://aiml-innovations.com/

AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its acquisition of Quantum Sciences Ltd. (100% owned by AIML), NeuralCloud Solutions Inc. (100% owned by AIML), and strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 11.11% currently owned by AIML), AI Rx Inc. (70% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors:

Mark Orsmond, Executive Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AI/ML Innovations, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the exercise price and vesting schedule for AIMLF's new stock options grant?

The stock options were granted at an exercise price of $0.105 per share, with vesting occurring 1/4 every 6 months over two years, starting from the grant date.

What are Dr. Alan Rabinowitz's qualifications and experience joining AIMLF?

Dr. Rabinowitz has over 20 years of experience in cardiology, serves as Clinical Associate Professor at UBC, was Director of Coronary Care at St. Paul's Hospital, and holds degrees from University of Cape Town, University of Toronto, and UBC.

What companies does AIMLF currently own or have partnerships with?

AIMLF owns 100% of Quantum Sciences and NeuralCloud Solutions, 95.2% of Health Gauge, 70% of AI Rx, and 11.11% of Tech2Heal with rights to increase to 22%.

What is AIMLF's current business focus and strategy?

AIMLF focuses on artificial intelligence and machine learning in digital health and wellbeing, investing in companies that leverage AI, ML, cloud computing and digital platforms for healthcare management solutions.